The molecular mechanism and challenge of targeting XPO1 in treatment of relapsed and refractory myeloma-Reference-Cited by-同舟云学术

登录注册会员服务联系我们

The molecular mechanism and challenge of targeting XPO1 in treatment of relapsed and refractory myeloma

Published:2022-08 Issue: Volume:22 Page:101448
ISSN:1936-5233
Container-title:Translational Oncology
language:en
Short-container-title:Translational Oncology

Author:

Sellin Mark,Berg Stephanie^ORCID,Hagen Patrick^ORCID,Zhang Jiwang^ORCID

Publisher

Elsevier BV

Subject

Cancer Research,Oncology

Reference197 articles.

1. Myeloma;Facts,2021

2. The global state of hematopoietic cell transplantation for multiple myeloma: an analysis of the worldwide network of blood and marrow transplantation database and the global burden of disease study;Cowan;Biol. Blood Marrow Transplant.,2020

3. Recent trends in multiple myeloma incidence and survival by age, race, and ethnicity in the United States;Costa;Blood Adv.,2017

4. Revised international staging system for multiple myeloma: a report from international myeloma working group;Palumbo;J. Clin. Oncol.,2015

5. Longer term follow-up of the randomized phase III trial SWOG S0777: bortezomib, lenalidomide and dexamethasone vs. lenalidomide and dexamethasone in patients (Pts) with previously untreated multiple myeloma without an intent for immediate autologous stem cell transplant (ASCT)

Cited by 7 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Efficacy and safety of selinexor for patients with relapsed and refractory multiple myeloma: A meta-analysis;Current Problems in Cancer;2024-06

2. Efficacy of Selinexor in Relapsed/Refractory Multiple Myeloma (RRMM) Patients with del17p and Other High-Risk Abnormalities (A Retrospective Single-Center Study);Life;2024-03-14

3. Real World Efficacy and Toxicity of Selinexor: Importance of Patient Characteristics, Dose Intensity and Post Progression Outcomes;Clinical Lymphoma Myeloma and Leukemia;2023-11

4. III. Current Treatment Strategies and Future Perspectives for Multiple Myeloma;Nihon Naika Gakkai Zasshi;2023-07-10

5. Nuclear Export Inhibitor Selinexor Enhances Oncolytic Myxoma Virus Therapy against Cancer;Cancer Research Communications;2023-06-01

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线，采集、加工和组织学术论文而形成的新型学术文献查询和分析系统，可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容，当前同舟云学术共收录了国内外主流学术期刊6万余种，收集的期刊论文及会议论文总量共计约1.5亿篇，并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询！咨询电话：010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号京ICP备18003416号-3